Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||New opportunities for targeting the androgen receptor in prostate cancer|
|Citation:||Cold Spring Harbor Perspectives in Medicine, 2018; 10(12):1-19|
|Publisher:||Cold Spring Harbor Laboratory Press|
|Margaret M. Centenera, Luke A. Selth, Esmaeil Ebrahimie, Lisa M. Butler and Wayne D. Tilley|
|Abstract:||Recent genomic analyses of metastatic prostate cancer have provided important insight into adaptive changes in androgen receptor (AR) signaling that underpin resistance to androgen deprivation therapies. Novel strategies are required to circumvent these AR-mediated resistance mechanisms and thereby improve prostate cancer survival. In this review, we present a summary of AR structure and function and discuss mechanisms of AR-mediated therapy resistance that represent important areas of focus for the development of new therapies.|
|Keywords:||Humans; Prostatic Neoplasms; Phenylthiohydantoin; Androstenes; Androgen Antagonists; Molecular Chaperones; Protein Isoforms; Receptors, Androgen; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Gene Amplification; Drug Resistance, Neoplasm; Mutation; Male; Molecular Targeted Therapy; Prostatic Neoplasms, Castration-Resistant|
|Rights:||Copyright © 2018 Cold Spring Harbor Laboratory Press; all rights reserved|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.